• Our Team

    Our Team

  • Chief Scientific Officer

    Dr Phil Jones

    Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council...

    LinkedIn Profile

  • Chief Executive Officer

    Paul Smith

    An experienced Senior Executive with both General Management and Business Development experience in the pharmaceutical/CRO arena. Paul has an understanding of the drug development process from discovery to clinical research gained through more than 29 years in th...

    LinkedIn Profile

  • Chief Operating Officer and Co-founder

    Dr Sylviane Boucharens

    Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent ...

    LinkedIn Profile

  • Chief Scientific Officer

    Dr Phil Jones

    Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council...

    LinkedIn Profile

  • Director of Chemistry

    Dr Angus Morrison

    Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he...

    LinkedIn Profile

  • Chief Operating Officer and Co-founder

    Dr Sylviane Boucharens

    Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma ...

    LinkedIn Profile

  • Director of Biosciences

    Dr Stuart McElroy

    With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Thr...

    LinkedIn Profile

  • Director of Chemistry

    Dr Angus Morrison

    Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he...

    LinkedIn Profile

  • Director of Biosciences

    Dr Stuart McElroy

    With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Thr...

    LinkedIn Profile

  • Chief Commercial Officer

    Dr Mike Piper

    Mike is an experienced life sciences professional with a track record in sales and marketing strategy, general management, licensing and contract negotiation.  Mike was formerly Head of Sales and Marketing at CXR Biosciences, an investigative toxicology CRO. Fol...

    LinkedIn Profile

Get In Touch

Let's talk about how we can maximise your drug discovery success.

Contact

Director of Chemistry

Dr Angus Morrison

Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he was Medicinal Chemistry lead of the European Lead Factory project responsible for over 30 hit to leads programmes.  Prior to this Angus has held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology. During his time in pre-clinical drug discovery he has had broad exposure and experience of working across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination.  Angus has a PhD in Organic Chemistry from Strathclyde University and carried out Postgraduate studies at Cambridge University. He is a co-author on over 30 papers and patents.

Director of Chemistry

Dr Angus Morrison

Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he was Medicinal Chemistry lead of the European Lead Factory project responsible for over 30 hit to leads programmes.  Prior to this Angus has held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology. During his time in pre-clinical drug discovery he has had broad exposure and experience of working across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination.  Angus has a PhD in Organic Chemistry from Strathclyde University and carried out Postgraduate studies at Cambridge University. He is a co-author on over 30 papers and patents..

Chief Commercial Officer

Dr Mike Piper

Mike is an experienced life sciences professional with a track record in sales and marketing strategy, general management, licensing and contract negotiation.  Mike was formerly Head of Sales and Marketing at CXR Biosciences, an investigative toxicology CRO. Following CXR’s acquisition by Concept Life Sciences in 2015 he became Vice President Business Development Safety & Toxicology.  Prior to his time at CXR, Mike worked in business development and licensing at the specialty pharmaceutical company Ardana plc, and held various pharmaceutical industry management consultancy roles at ZS Associates, Deloitte and Arthur Andersen Business Consulting.  Mike has a PhD in genomics from the University of Cambridge, MRC Laboratory of Molecular Biology.

Chief Scientific Officer

Dr Phil Jones

Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council at Schering-Plough. Numerous clinical candidates resulted from groups for which he was responsible. These span a broad range of target families and therapeutic areas. He has led the European Screening Centre team at Biocity Scotland, Newhouse for the past 5 years and this group plays a key role in delivering validated hit series for SMEs and academics through the IMI funded European Lead Factory. Phil’s postgraduate studies were carried out at the University of Manchester and Imperial College. Phil was elected a Fellow of the Royal Society of Chemistry in 2005, he chaired the Medicinal Chemistry interest group of the Royal Society of Chemistry for 8 years, chaired the organising committee of the European Federation of Medicinal Chemistry – International Symposium on Medicinal Chemistry (EFMC-ISMC) in 2016 and sat on the Executive Committee of the EFMC for four years. He is a co-author on over 70 scientific papers and patents.

Chief Scientific Officer

Dr Phil Jones

Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council at Schering-Plough. Numerous clinical candidates resulted from groups for which he was responsible. These span a broad range of target families and therapeutic areas. He has led the European Screening Centre team at Biocity Scotland, Newhouse for the past 5 years and this group plays a key role in delivering validated hit series for SMEs and academics through the IMI funded European Lead Factory. Phil’s postgraduate studies were carried out at the University of Manchester and Imperial College. Phil was elected a Fellow of the Royal Society of Chemistry in 2005, he chaired the Medicinal Chemistry interest group of the Royal Society of Chemistry for 8 years, chaired the organising committee of the European Federation of Medicinal Chemistry – International Symposium on Medicinal Chemistry (EFMC-ISMC) in 2016 and sat on the Executive Committee of the EFMC for four years. He is a co-author on over 70 scientific papers and patents.

Director of Biosciences

Dr Stuart McElroy

With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Throughout the 5 years of the European Lead Factory project he held the position of Head of Biology at the European Screening Centre (ESC), leading a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Prior to this Stuart helped establish the Dundee Drug Discovery Unit (DDU) where he spent 7 years as a project and then team leader working across a wide array of novel drug targets and assays. He also had a leading operational role in DDU-Industry partnerships with both large pharma and SMEs.

Director of Biosciences

Dr Stuart McElroy

With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Throughout the 5 years of the European Lead Factory project he held the position of Head of Biology at the European Screening Centre (ESC), leading a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Prior to this Stuart helped establish the Dundee Drug Discovery Unit (DDU) where he spent 7 years as a project and then team leader working across a wide array of novel drug targets and assays. He also had a leading operational role in DDU-Industry partnerships with both large pharma and SMEs.

Chief Operating Officer and Co-founder

Dr Sylviane Boucharens

Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent Sylviane was Head of Global Compound repository and in-vitro Screening (Merck Sharp & Dohme, Newhouse Scotland). She was also responsible for managing a portfolio of early Drug Discovery projects in Cardiovascular from Target Identification and validation to Lead Optimisation. Sylviane attained her PhD in Cellular and Molecular Biology from the University Joseph Fourier, Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, France and University of Manchester, UK under the Wellcome Trust International Fellowship.

Chief Operating Officer and Co-founder

Dr Sylviane Boucharens

Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent Sylviane was Head of Global Compound repository and in-vitro Screening (Merck Sharp & Dohme, Newhouse Scotland). She was also responsible for managing a portfolio of early Drug Discovery projects in Cardiovascular from Target Identification and validation to Lead Optimisation. Sylviane attained her PhD in Cellular and Molecular Biology from the University Joseph Fourier, Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, France and University of Manchester, UK under the Wellcome Trust International Fellowship.

Chief Executive Officer

Paul Smith

An experienced Senior Executive with both General Management and Business Development experience in the pharmaceutical/CRO arena. Paul has an understanding of the drug development process from discovery to clinical research gained through more than 29 years in the CRO/pharmaceutical sector. A strategic thinker and management professional with experience gained in both small and large companies and with recent start-up experience including leading  funding discussions with VCs and other corporate finance groups. Paul recently turned around and sold CXR Biosciences to Concept Lifesciences in late 2015. Elected Fellow of the Royal Society of Biology, 2013.